Enhancing the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer With Immunotherapy-Based Regimens

HYBRID EVENT

OVERVIEW
Non-muscle invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder cancers. The condition has a wide range of progression and recurrence rates that are clinically understood and managed through established risk stratification models. Patients with high-risk NMIBC (HR-NMIBC) are at the greatest risk for recurrence after treatment and progression to metastatic disease. Join us for a lively, interactive session that will address risk-stratifying patients, identifying eligibility for treatment and maintenance, optimally selecting treatments for patients with HR-NMIBC, and recognizing emerging regimens that could shift the treatment paradigm.

REGISTER HERE: www.medscape.org/symposium/hrnmibc-urologist2023

AGENDA:

SATURDAY, APRIL 29, 2023

6:00 pm: Registration and Meal

6:30 pm: Welcome and Introductions

6:35 pm: Understanding HR-NMIBC

6:50 pm: Current Treatment Landscape for Management of HR-NMIBC

7:10 pm: Immunotherapy-Based Treatment Regimens for the Management of HR-NMIBC

7:30 pm: Emerging Therapies and the Clinical Data

7:50 pm: Panel Discussion and Audience Q&A

8:00 pm: Program Conclusion

TARGET AUDIENCE
This activity is intended for urologists, oncologists, including uro-oncologists, pathologists, and other clinicians who care for individuals with bladder cancer.

ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL STATEMENT
The goal of this activity is for learners to be better able to improve their understanding of immunotherapy-based regimens in the care of patients with HR-NMIBC.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:
Have increased knowledge regarding the
Identification of patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC)
Role of immunotherapy combination strategies in the management of HR-NMIBC
Clinical data associated with the emerging immunotherapy combination strategies for the management of HR-NMIBC

Have greater competence related to
Diagnosing and risk-stratifying patients with HR-NMIBC using up-to-date guidelines

Demonstrate greater confidence in their ability to
Identify the urologist’s role in the management of patients with HR-NMIBC

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP and Pfizer.